Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    SAB Biotherapeutics Inc.

    NASDAQ: SABS · Real-Time Price · USD
    1.72
    0.02 (1.18%)
    At close: Jun 17, 2025, 2:39 PM

    SAB Biotherapeutics Statistics

    Share Statistics

    SAB Biotherapeutics has 9.29M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 9.29M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 28.38%

    Shares Floating

    n/a
    		 7.49M

    Failed to Deliver (FTD) Shares

    n/a
    		 3,350

    FTD / Avg. Volume

    n/a
    		 7.76%

    Short Selling Information

    The latest short interest is 36.81K, so 0.4% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 36.81K

    Short % of Shares Out

    n/a
    		 0.4%

    Short % of Float

    n/a
    		 0.5%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -1.03 and the forward PE ratio is -1.35. SAB Biotherapeutics's PEG ratio is 0.02.

    PE Ratio

    n/a
    		 -1.03

    Forward PE

    n/a
    		 -1.35

    PS Ratio

    n/a
    		 26.54

    Forward PS

    n/a
    		 0.3

    PB Ratio

    n/a
    		 1.35

    P/FCF Ratio

    n/a
    		 -1.01

    PEG Ratio

    n/a
    		 0.02
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for SAB Biotherapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.98, with a Debt / Equity ratio of 0.18.

    Current Ratio

    n/a
    		 2.98

    Quick Ratio

    n/a
    		 2.98

    Debt / Equity

    n/a
    		 0.18

    Debt / EBITDA

    n/a
    		 -0.16

    Debt / FCF

    n/a
    		 -0.13

    Interest Coverage

    n/a
    		 -134.77

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $20,984.13

    Profits Per Employee

    n/a
    		 $-541,349.21

    Employee Count

    n/a
    		 63

    Asset Turnover

    n/a
    		 0.03

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -47.69% in the last 52 weeks. The beta is 0.55, so SAB Biotherapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.55

    52-Week Price Change

    n/a
    		 -47.69%

    50-Day Moving Average

    n/a
    		 1.66

    200-Day Moving Average

    n/a
    		 2.5

    Relative Strength Index (RSI)

    n/a
    		 43.78

    Average Volume (20 Days)

    n/a
    		 43,144

    Income Statement

    In the last 12 months, SAB Biotherapeutics had revenue of 1.32M and earned -34.1M in profits. Earnings per share was -3.68.

    Revenue

    n/a
    		 1.32M

    Gross Profit

    n/a
    		 -3.47M

    Operating Income

    n/a
    		 -42.91M

    Net Income

    n/a
    		 -34.1M

    EBITDA

    n/a
    		 -28.99M

    EBIT

    n/a
    		 -33.79M

    Earnings Per Share (EPS)

    n/a
    		 -3.68
    Full Income Statement

    Balance Sheet

    The company has 8.9M in cash and 4.67M in debt, giving a net cash position of 4.23M.

    Cash & Cash Equivalents

    n/a
    		 8.9M

    Total Debt

    n/a
    		 4.67M

    Net Cash

    n/a
    		 4.23M

    Retained Earnings

    n/a
    		 -124.17M

    Total Assets

    n/a
    		 38.12M

    Working Capital

    n/a
    		 6.64M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -34.29M and capital expenditures -337.26K, giving a free cash flow of -34.63M.

    Operating Cash Flow

    n/a
    		 -34.29M

    Capital Expenditures

    n/a
    		 -337.26K

    Free Cash Flow

    n/a
    		 -34.63M

    FCF Per Share

    n/a
    		 -3.74
    Full Cash Flow Statement

    Margins

    Gross margin is -262.41%, with operating and profit margins of -3244.87% and -2579.03%.

    Gross Margin

    n/a
    		 -262.41%

    Operating Margin

    n/a
    		 -3244.87%

    Pretax Margin

    n/a
    		 -2579.03%

    Profit Margin

    n/a
    		 -2579.03%

    EBITDA Margin

    n/a
    		 -2192.54%

    EBIT Margin

    n/a
    		 -3245.92%

    FCF Margin

    n/a
    		 -2619.46%

    Dividends & Yields

    SABS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for SABS is $11, which is 547.1% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $11

    Price Target Difference

    n/a
    		 547.1%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 4
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Jan 5, 2024. It was a backward split with a ratio of 1:10.

    Last Split Date

    n/a
    		 Jan 5, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:10

    Scores

    Altman Z-Score

    n/a
    		 -7.36

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist